Challenges in the management of juvenile idiopathic arthritis with etanercept.
Biologic agents have been designed with the help of immunological studies to target particular areas of the immune system which are thought to play a role in the pathogenesis of disease. Etanercept is a soluble anti-tumor necrosis factor alpha (TNF-alpha) agent licensed for the treatment of active poly-articular juvenile idiopathic arthritis (JIA) in children aged 4 to 17 years who have failed to respond to methotrexate alone, or who have been intolerant of methotrexate. The safety and efficacy of etanercept in this patient group has been established by one randomized controlled trial and several longitudinal studies. This, together with the fact that until recently etanercept was the only anti-TNF licensed in JIA, has made it the most common first choice biologic for many clinicians. However, there are still many unanswered questions about etanercept, including its efficacy and safety in different subtypes of JIA, in children under 4 years of age and in those with uveitis. There are still concerns about the long term safety of TNF antagonists in the pediatric age group and unanswered questions about increased risks of malignancy and infection. Although adult studies are useful to improve understanding of these risks, they are not a substitute for good quality pediatric research and follow-up studies. Adult trials often include greater numbers of patients. However, they evaluate a different population and drug behavior may vary in children due to differences in metabolism, growth and impact on a developing immune system. In addition, rheumatoid arthritis is a different disease than JIA. Clinicians need to carefully weigh up the risk benefit ratio of anti-TNF use in children with JIA and push for robust clinical trials to address the questions that remain unanswered. This article summarizes the evidence available for use of etanercept in children with JIA and highlights aspects of treatment in need of further research.
Pain
Clare E
CE
Alder Hey Children's NHS Foundation Trust, Eaton Road, Liverpool, UK.
McCann
Liza J
LJ
Rheumatol Int. 2007 Dec;28(2):153-6
17641897
Ann Rheum Dis. 2003 Mar;62(3):245-7
12594111
Arthritis Rheum. 2003 Apr;48(4):1093-101
12687553
Ann Rheum Dis. 2007 Apr;66(4):548-50
17068061
J Rheumatol. 2004 Feb;31(2):390-2
14760812
Arthritis Rheum. 2001 Jun;44(6):1411-5
11407702
Arthritis Rheum. 2007 May;56(5):1433-9
17469100
Arthritis Rheum. 2004 Jul;50(7):2191-201
15248217
Ann Rheum Dis. 2009 Apr;68(4):552-7
18467515
Rheumatology (Oxford). 2002 Dec;41(12):1436-9
12468826
J Exp Med. 2005 May 2;201(9):1479-86
15851489
J Rheumatol. 2007 May;34(5):1146-50
17343318
Arthritis Rheum. 2003 Mar;48(3):767-75
12632431
Arthritis Rheum. 2005 Feb 15;53(1):18-23
15696578
J Rheumatol. 2001 Jul;28(7):1677-80
11469478
Arthritis Rheum. 2001 Dec;44(12):2862-9
11762947
Pediatr Blood Cancer. 2008 Feb;50(2):419-21
16900487
Medicine (Baltimore). 2007 Jul;86(4):242-251
17632266
Arthritis Rheum. 2004 Jul;50(7):2264-72
15248226
Ophthalmology. 2001 Nov;108(11):2071-5
11713082
Arthritis Rheum. 2000 Nov;43(11):2606-8
11083287
Cytokine. 2008 Jun;42(3):293-7
18445529
J Rheumatol. 2007 Dec;34(12):2481-5
18050366
Arthritis Rheum. 2006 Jun;54(6):1987-94
16732547
Arthritis Rheum. 2003 Jan;48(1):218-26
12528122
Ann Rheum Dis. 2008 Aug;67(8):1145-52
17981916
Ann Rheum Dis. 2004 Dec;63(12):1638-44
15115709
Acta Reumatol Port. 2007 Jan-Mar;32(1):15-26
17450761
J Clin Pharmacol. 2005 Mar;45(3):246-56
15703360
Clin Rheumatol. 1998;17(4):288-92
9776110
Clin Rheumatol. 2007 Aug;26(8):1332-4
17597334
Arthritis Rheum. 1995 Feb;38(2):211-20
7848311
Clin Exp Rheumatol. 2003 Mar-Apr;21(2):276-7
12747299
Ann Rheum Dis. 2009 May;68(5):635-41
18413443
Clin Exp Rheumatol. 2002 Sep-Oct;20(5):723-6
12412209
Rheumatology (Oxford). 2002 Dec;41(12):1444-9
12468828
Arthritis Rheum. 2003 Nov;48(11):3230-6
14613288
Arthritis Rheum. 1997 Jul;40(7):1202-9
9214419
Ann Rheum Dis. 2009 Apr;68(4):519-25
18413440
Rheumatology (Oxford). 2005 Aug;44(8):1008-11
15855187
Clin Rheumatol. 2001;20(1):30-5
11254238
Arthritis Rheum. 2006 Apr;54(4):1063-74
16572441
Ann Rheum Dis. 2007 May;66(5):704-5
17324973
J Rheumatol. 2003 Feb;30(2):401-3
12563702
Clin Exp Rheumatol. 2008 Jul-Aug;26(4):688-92
18799107
Rheumatol Int. 2008 Aug;28(10):1031-4
18369626
Ann Rheum Dis. 2006 Aug;65(8):1044-9
16449314
Arch Dermatol. 2001 Jul;137(7):893-9
11453808
J Rheumatol Suppl. 2005 Mar;74:26-30
15742461
Arthritis Rheum. 2006 Jun;54(6):1786-94
16736520
J Rheumatol. 2006 Jun;33(6):1186-8
16755667
J Rheumatol. 1997 Jul;24(7):1403-9
9228145
Ann Rheum Dis. 2001 Apr;60(4):410-2
11247875
Clin Drug Investig. 2003;23(8):511-8
17535063
Drug Saf. 2008;31(5):445-7
18422389
N Engl J Med. 2000 Mar 16;342(11):763-9
10717011
J Rheumatol. 2005 May;32(5):935-42
15868633
J Rheumatol Suppl. 2005 Mar;74:3-7
15742457
Rheumatology (Oxford). 2002 Dec;41(12):1440-3
12468827
Ann Rheum Dis. 2004 Dec;63(12):1594-600
15345498
J Rheumatol. 2007 Dec;34(12):2503-4
18061971
Lancet. 2008 Aug 2;372(9636):383-91
18632147
Ann Rheum Dis. 2007 Nov;66(11):1518-24
17491099
J Rheumatol. 2004 Oct;31(10):2055-61
15468375
Clin Exp Rheumatol. 2002 Nov-Dec;20(6):867-70
12508784
Lancet. 2008 Mar 22;371(9617):998-1006
18358927
Nat Clin Pract Rheumatol. 2006 Nov;2(11):602-10
17075599
Clin Exp Rheumatol. 2002 Nov-Dec;20(6 Suppl 28):S137-42
12463465
Curr Rheumatol Rep. 2005 Dec;7(6):434-40
16303102
Arthritis Rheum. 2008 May;58(5):1496-504
18438876
J Pediatr Gastroenterol Nutr. 2004 Aug;39(2):203-6
15269630
Rheumatology (Oxford). 2002 Dec;41(12):1428-35
12468825
Rheumatol Int. 2009 Mar;29(5):591-3
18810448
Ann Rheum Dis. 2002 Feb;61(2):171-3
11796406
Clin Exp Rheumatol. 1994 Sep-Oct;12(5):561-5
7531125
Ann Rheum Dis. 2005 Jun;64(6):875-80
15897308
Arthritis Rheum. 2000 Aug;43(8):1849-57
10943876